Abstract
Biological agents (biologicals) are an invaluable resource in the treatment of patients with severe immunopathological diseases, especially non-responsive or intolerant to conventional therapies. However, they represent a significant economic burden to healthcare systems.
Since biosimilars are similar and more affordable versions of original drugs, they are expected to contribute to healthcare system sustainability and reduce inequities in treatment access. The current article summarizes the importance of biosimilars, with an emphasis on newly available biosimilar adalimumab and its use in inflammatory bowel disease.